TB Biosciences, Inc., a Bethlehem, PA-based development-stage company, secured $1.5m in Series A financing.
The round was led by Originate Ventures with participation from Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund.
The company intends to use the funds for product development and clinical trials.
founded in June 2013 by Sam Niedbala, Ph.D., CEO, TB Biosciences develops a rapid point-of-care tuberculosis test that meets performance standards around the world. Its target is to commercialize a tuberculosis test that replaces the 125 year old sputum smear test. The Company is using an array of patented peptides developed and exclusively licensed from the NYU School of Medicine.